Guzmán-Esquivel, J.; Garcia-Garcia, H.S.; Hernández-Fuentes, G.A.; Venegas-RamÃrez, J.; Barajas-MejÃa, C.D.; Garza-Veloz, I.; Martinez-Fierro, M.L.; Magaña-Vergara, N.E.; Guzmán-Solórzano, J.A.; Calvo-Soto, P.;
et al. The Impact of Doxycycline as an Adjunctive Therapy on Prostate-Specific Antigen, Quality of Life, and Cognitive Function in Metastatic Prostate Cancer Patients: A Phase II Randomized Controlled Trial. Pharmaceutics 2025, 17, 404.
https://doi.org/10.3390/pharmaceutics17040404
AMA Style
Guzmán-Esquivel J, Garcia-Garcia HS, Hernández-Fuentes GA, Venegas-RamÃrez J, Barajas-MejÃa CD, Garza-Veloz I, Martinez-Fierro ML, Magaña-Vergara NE, Guzmán-Solórzano JA, Calvo-Soto P,
et al. The Impact of Doxycycline as an Adjunctive Therapy on Prostate-Specific Antigen, Quality of Life, and Cognitive Function in Metastatic Prostate Cancer Patients: A Phase II Randomized Controlled Trial. Pharmaceutics. 2025; 17(4):404.
https://doi.org/10.3390/pharmaceutics17040404
Chicago/Turabian Style
Guzmán-Esquivel, José, Hossana S. Garcia-Garcia, Gustavo A. Hernández-Fuentes, Jesús Venegas-RamÃrez, Carlos D. Barajas-MejÃa, Idalia Garza-Veloz, Margarita L. Martinez-Fierro, Nancy E. Magaña-Vergara, José A. Guzmán-Solórzano, Patricia Calvo-Soto,
and et al. 2025. "The Impact of Doxycycline as an Adjunctive Therapy on Prostate-Specific Antigen, Quality of Life, and Cognitive Function in Metastatic Prostate Cancer Patients: A Phase II Randomized Controlled Trial" Pharmaceutics 17, no. 4: 404.
https://doi.org/10.3390/pharmaceutics17040404
APA Style
Guzmán-Esquivel, J., Garcia-Garcia, H. S., Hernández-Fuentes, G. A., Venegas-RamÃrez, J., Barajas-MejÃa, C. D., Garza-Veloz, I., Martinez-Fierro, M. L., Magaña-Vergara, N. E., Guzmán-Solórzano, J. A., Calvo-Soto, P., Avila-Zamora, O. N., Fuentes-Murguia, M., Ceja-EspÃritu, G., & Delgado-Enciso, I.
(2025). The Impact of Doxycycline as an Adjunctive Therapy on Prostate-Specific Antigen, Quality of Life, and Cognitive Function in Metastatic Prostate Cancer Patients: A Phase II Randomized Controlled Trial. Pharmaceutics, 17(4), 404.
https://doi.org/10.3390/pharmaceutics17040404
